MedTrace Logo

HLA Haploidentical Bone Marrow Transplant in Patients With Severe Sickle Cell Disease

NCT03240731 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2025-09-02

No results posted yet for this study

Summary

multicentric interventional biomedical research phase II, prospective, non-randomized evaluating a haploidentical marrow transplants after reduced-intensity conditioning and prevention of GvHD based on cyclophosphamide administration post transplantation in patients with severe sickle cell disease.

Conditions

Interventions

BIOLOGICAL

bone marrow transplant

haploidentical bone marrow transplant

Sponsors & Collaborators

  • Keocyt

    collaborator UNKNOWN

  • Association Clinique Thérapeutique Infantile du val de Marne

    collaborator OTHER

  • Centre Hospitalier Intercommunal Creteil

    lead OTHER

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
13 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-10
Primary Completion
2024-04-08
Completion
2024-04-08

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03240731 on ClinicalTrials.gov